A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome

Br J Dermatol. 2020 Feb;182(2):497-498. doi: 10.1111/bjd.18522. Epub 2019 Oct 13.

Authors

T Papps¹, C McCormack¹, O Buelens¹, C Van der Weyden¹, R Twigger¹, B A Campbell², M Dickinson¹, H M Prince^{1

3}

Affiliations

¹ Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Australia.
² Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
³ Molecular Oncology and Cancer Immunology Epworth Healthcare, East Melbourne, Victoria, Australia.

PMID: 31512229
DOI: 10.1111/bjd.18522

No abstract available

Publication types

Letter

MeSH terms

Histone Deacetylase Inhibitors / therapeutic use
Humans
Mycosis Fungoides* / drug therapy
Sezary Syndrome* / drug therapy
Skin Neoplasms* / drug therapy

Substances

Histone Deacetylase Inhibitors